Pharmacotherapy for Cirrhosis in Japan DOI Creative Commons

Hiroki Nishikawa,

Soo Ki Kim, Akira Asai

et al.

Portal hypertension & cirrhosis, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

ABSTRACT Cirrhosis is a terminal manifestation of chronic liver disease, regardless its cause, and was previously considered an irreversible condition. As cirrhosis progresses from the compensated to decompensated stage, disease‐related events such as varices, ascites, encephalopathy, sarcopenia, jaundice, bleeding tendency, well carcinogenesis, can occur at high rate, regenerative capacity eventually fails. With advent new pharmacotherapies for in last decade, fibrosis has been shown improve with appropriate intervention, prognosis cirrhotic patients improved dramatically. According published data Japan Society Hepatology, although hepatitis C virus (HCV) used be leading cause Japan, alcoholic overtaken HCV thus major paradigm shift occurred this field. There are mainly two approaches pharmacotherapy cirrhosis: (1) eliminating underlying (2) treating cirrhosis‐related complications. This review article outlines efficacy clinical impact drugs currently covered by insurance treatment cirrhosis.

Language: Английский

Pharmacotherapy for Cirrhosis in Japan DOI Creative Commons

Hiroki Nishikawa,

Soo Ki Kim, Akira Asai

et al.

Portal hypertension & cirrhosis, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

ABSTRACT Cirrhosis is a terminal manifestation of chronic liver disease, regardless its cause, and was previously considered an irreversible condition. As cirrhosis progresses from the compensated to decompensated stage, disease‐related events such as varices, ascites, encephalopathy, sarcopenia, jaundice, bleeding tendency, well carcinogenesis, can occur at high rate, regenerative capacity eventually fails. With advent new pharmacotherapies for in last decade, fibrosis has been shown improve with appropriate intervention, prognosis cirrhotic patients improved dramatically. According published data Japan Society Hepatology, although hepatitis C virus (HCV) used be leading cause Japan, alcoholic overtaken HCV thus major paradigm shift occurred this field. There are mainly two approaches pharmacotherapy cirrhosis: (1) eliminating underlying (2) treating cirrhosis‐related complications. This review article outlines efficacy clinical impact drugs currently covered by insurance treatment cirrhosis.

Language: Английский

Citations

0